Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VivoSim Labs, INC.ONVO · Entity 8386 | CSO & EVP Pre-Clinical Dev | November 16, 2017 | November 17, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VivoSim Labs, INC.
Report date November 16, 2017 · Filed November 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 876,609 |
Reported balance
After 2017-11-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-11-16 · Tax withholding · Disposed 5,625 · Balance 876,609 F1: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2: This number does not include 1,070,000 shares of common stock underlying outstanding options held by Dr. David; post-transaction Dr. David beneficially owns or has a right to acquire 1,946,609 shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer.
F2: This number does not include 1,070,000 shares of common stock underlying outstanding options held by Dr. David; post-transaction Dr. David beneficially owns or has a right to acquire 1,946,609 shares of common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2017 Filed Nov 17, 2017 00:46 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 5,625 | $1.47 | $8,269.88 |
DisclosureSEC source: 0001209191-17-061324 · doc4.xml · nonDerivative · entry 1 David Eric · CIK 0001549671 · CSO & EVP Pre-Clinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 876,609 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,070,000 shares of common stock underlying outstanding options held by Dr. David; post-transaction Dr. David beneficially owns or has a right to acquire 1,946,609 shares of common stock. Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 20:49 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 8,469 | $2.06 | $17,446.14 |
DisclosureSEC source: 0001209191-17-049422 · doc4.xml · nonDerivative · entry 1 David Eric · CIK 0001549671 · CSO & EVP Pre-Clinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,234 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,070,000 shares of common stock underlying outstanding options held by Dr. David; post-transaction Dr. David beneficially owns or has a right to acquire 1,952,234 shares of common stock. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:13 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantCommon Stock | 190,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-042350 · doc4.xml · nonDerivative · entry 1 David Eric · CIK 0001549671 · CSO & EVP Pre-Clinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,703 F1 · security: Annual long-term equity award approved by the Compensation Committee of the Issuer's Board of Directors. F2 · shares: The shares represent a grant of Restricted Stock Units ("RSUs"). The RSUs represent a right to receive shares of the Issuer's common stock, at no additional conversion or exercise price. The RSUs vest and settle over 16 equal quarterly installments measured from May 15, 2017. F3 · balance_after: This number does not include 1,070,000 shares of common stock underlying outstanding options held by Dr. David; post-transaction Dr. David beneficially owns or has a right to acquire 1,960,703 shares of common stock. Read SEC document |
| May 16, 2017 Filed May 17, 2017 23:07 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 1,263 | $2.86 | $3,614.83 |
DisclosureSEC source: 0001209191-17-033415 · doc4.xml · nonDerivative · entry 1 David Eric · CIK 0001549671 · CSO & EVP Pre-Clinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,703 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,070,000 shares of common stock underlying outstanding options held by Dr. David; post-transaction Dr. David continues to beneficially own or have a right to acquire 1,770,703 shares of common stock. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:59 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 1,390 | $2.95 | $4,100.50 |
DisclosureSEC source: 0001209191-17-012847 · doc4.xml · nonDerivative · entry 1 David Eric · CIK 0001549671 · CSO & EVP Pre-Clinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701,966 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,070,000 shares of common stock underlying outstanding options held by Dr. David; post-transaction Dr. David continues to beneficially own or have a right to acquire 1,771,966 shares of common stock. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 22:06 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 1,745 | $3.26 | $5,687.65 |
DisclosureSEC source: 0001209191-16-151268 · doc4.xml · nonDerivative · entry 1 David Eric · CIK 0001549671 · CSO & EVP Pre-Clinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,356 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,070,000 shares of common stock underlying outstanding options held by Dr. David; post-transaction Dr. David continues to beneficially own or have a right to acquire 1,773,356 shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.